CN105646354A - 一种咪唑类化合物 - Google Patents
一种咪唑类化合物 Download PDFInfo
- Publication number
- CN105646354A CN105646354A CN201610163381.4A CN201610163381A CN105646354A CN 105646354 A CN105646354 A CN 105646354A CN 201610163381 A CN201610163381 A CN 201610163381A CN 105646354 A CN105646354 A CN 105646354A
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- tumor
- mice
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title abstract description 10
- -1 Imidazole compound Chemical class 0.000 title abstract description 5
- 230000000202 analgesic effect Effects 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 2
- 230000004614 tumor growth Effects 0.000 abstract description 2
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 16
- 229960000590 celecoxib Drugs 0.000 description 12
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 12
- 239000000376 reactant Substances 0.000 description 11
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 10
- ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000001382 Experimental Melanoma Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- XDCOYBQVEVSNNB-UHFFFAOYSA-N 4-[(7-naphthalen-2-yl-1-benzothiophen-2-yl)methylamino]butanoic acid Chemical compound OC(=O)CCCNCc1cc2cccc(-c3ccc4ccccc4c3)c2s1 XDCOYBQVEVSNNB-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- ALIVXCSEERJYHU-UHFFFAOYSA-N Flurbiprofen axetil Chemical compound FC1=CC(C(C)C(=O)OC(OC(C)=O)C)=CC=C1C1=CC=CC=C1 ALIVXCSEERJYHU-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- OQKFGIANPCRSSK-UHFFFAOYSA-N azanium;methanol;acetate Chemical compound [NH4+].OC.CC([O-])=O OQKFGIANPCRSSK-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229940085928 celecoxib 200 mg Drugs 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229950005941 flurbiprofen axetil Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical class CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种咪唑类化合物(式Ⅰ所示)及其盐,实验证明具有较好的药动学参数、抑瘤活性和镇痛作用,可以抑制肿瘤细胞的生长,用于制备抗肿瘤和镇痛药物。
Description
技术领域
本发明涉及一种咪唑类化合物。
背景技术
非甾类抗炎药(NSAIDS)通过抑制前列腺素的合成显示其特有的抗炎、退热和镇痛效果,目前临床上应用较为广泛的是阿司匹林、布洛芬、酮洛芬、氟比洛芬酯、双氯芬酸钠、塞来昔布、帕瑞昔布和萘普生等。在已公开的文献中化合物Z为塞来昔布的前体药物,结构式如下:
Z
在公开的文献中介绍了化合物Z较塞来昔布具有较好的药动学参数。
肿瘤是危害人类健康的严重疾病,肿瘤的防治工作一直是医药研究领域的重点。目前,由于工业发展中带来的环境污染等问题,人类的生存环境质量不断下降,造成肿瘤疾病的发病率与致死率不断上升。放疗、化疗是目前治疗肿瘤的主要手段。但化疗、放疗在抑制了癌细胞发育的同时也抑制了正常细胞的发育,降低了机体免疫力,导致新的并发症。治疗肿瘤疾病的特效药并不能令人满意,目前临床所用细胞毒性药物选择性不高,导致对正常细胞的恶性杀伤,限制了其应用。因此,寻找新的、无创伤、无细胞毒作用的抗肿瘤药物成为国际医药领域的重要方向。
发明内容
我公司研究人员进一步合成了化合物1a、1b、1c(式Ⅰ化合物的钠盐),进行体外、体内抗肿瘤实验和药动学试验,比较塞来昔布、化合物Z、1a、1b和1c的抑瘤活性及药动学参数。
式(Ⅰ)
我们所合成的系列化合物可以通过实施例中的反应路线取得。
将下述化合物1a、1b、1c、化合物Z、塞来昔布进行抑瘤试验比较,发现对于黑色素瘤B16的抑制作用1c(式Ⅰ)明显大于其它化合物。将上述化合物1a、1b、1c、化合物Z、塞来昔布进行药动学试验,发现1a、1b、1c、Z化合物经过beagle犬灌胃后在血液中均不同程度的代谢为塞来昔布,其中1c具有最佳的药动学特征,beagle犬灌胃后观察到的AUC值显著大于其它化合物,镇痛作用也由于化合物Z。
具体实施例:
实施例1:系列化合物的制备:
1a、1b、1c依照下式获得:
(1)化合物3的合成:
准确称取32.4克甲醇钠加入到100.0mLDMF中,在室温下搅拌反应10分钟,反应液冷却至5-10℃,缓慢滴加67.0克对甲基苯乙酮,用时30分钟,滴加完毕后继续反应30分钟。将76.8克三氟乙酸甲酯溶于100mL的DMF中,缓慢滴加到上述反应液中,用时30分钟,滴加完毕后在室温下继续反应1小时,停止反应,向反应液中加入300mL冰水,用37%的盐酸调节pH=3-5,充分搅拌30分钟,抽滤,滤饼用蒸馏水洗涤(200mL×3),真空干燥得到101.8克淡黄色的化合物3,产率为87.7%。HNMR(400Hz,DMSO):7.74-7.72(d,J=4.4Hz,2H),7.18-7.16(d,J=4.4Hz,2H),3.71(s,2H),2.35(s,3H);MS(m/z):231.3。
(2)化合物4的合成:
准确称取89.4克4-(氨基磺酰基)苯肼和30.0mL37%的盐酸加入到200.0mL的DMF中,搅拌反应30分钟,向反应液中加入100克化合物3,60℃下搅拌反应2小时,停止反应,反应液冷却至室温,向反应液中加入500mL蒸馏水,充分搅拌1小时,抽滤,滤饼用蒸馏水洗涤(200mL×3),真空干燥后得到149.8克化合物4,产率为90.3%。HNMR(400Hz,DMSO):7.92-7.90(d,J=4.8Hz,2H),7.50-7.48(d,J=4.8Hz,2H),7.37-7.35(d,J=4.4Hz,2H),7.18-7.16(d,J=4.4Hz,2H),6.55(s,2H),2.35(s,3H);MS(m/z):382.3。
(3)化合物5a(R为甲基)、5b(R为乙基)、5c(R为环丙基)的合成:
准确称取38.1克化合物4和15.0克三乙胺加入到200.0mL的DCM中,搅拌反应30分钟,向反应液中滴加11.0克丙酰氯,10分钟内滴加完毕,升温至60℃下搅拌反应2小时,停止反应,反应液冷却至室温,向反应液中加入500mL蒸馏水,充分搅拌1小时,静置分层,分出有机层,水层用DCM萃取(100mL×3),合并有机相,用蒸馏水洗涤(200mL×3),减压蒸馏除去溶剂得到35.6克化合物5a,产率为81.3%。HNMR(400Hz,DMSO):8.00(s,1H),7.92-7.90(d,J=4.8Hz,2H),7.50-7.48(d,J=4.8Hz,2H),7.37-7.35(d,J=4.4Hz,2H),7.18-7.16(d,J=4.4Hz,2H),6.55(s,2H),2.35(s,3H),2.24-2.20(m,2H),1.14(t,J=3.6Hz,3H);MS(m/z):438.3。
重复上述的反应步骤,得到36.4克化合物5b,产率为80.3%。HNMR(400Hz,DMSO):8.00(s,1H),7.92-7.90(d,J=4.8Hz,2H),7.50-7.48(d,J=4.8Hz,2H),7.37-7.35(d,J=4.4Hz,2H),7.18-7.16(d,J=4.4Hz,2H),6.55(s,2H),2.35(s,3H),2.19-2.17(m,2H),1.63-1.61(m,2H),0.96(t,J=3.2Hz,3H);MS(m/z):453.3。
重复上述的反应步骤,得到33.8克化合物5c,产率为74.9%。HNMR(400Hz,DMSO):8.00(s,1H),7.92-7.90(d,J=4.8Hz,2H),7.50-7.48(d,J=4.8Hz,2H),7.37-7.35(d,J=4.4Hz,2H),7.18-7.16(d,J=4.4Hz,2H),6.55(s,2H),2.35(s,3H),1.19-1.17(m,1H),0.71-0.68(m,2H),0.56-0.52(m,2H);MS(m/z):451.3。
(4)化合物1a、1b、1c的合成:
准确称取30.0克化合物5a加入到100.0mL的乙醇中,室温下搅拌30分钟。将2.9克氢氧化钠(与其他无机碱或有机碱如氨丁三醇、氢氧化钾、氢氧化镁、二乙胺、三乙胺、匍胺等可获得不同的盐)或溶于50.0mL乙醇中,滴加到上述反应液中,10分钟内滴加完毕,室温下搅拌反应2小时,停止反应,向反应液中缓慢滴加300mL乙醚,这时有大量的沉淀析出,充分搅拌1小时,抽滤,滤饼用乙醚洗涤(50.0mL×3),真空干燥后得到25.3克化合物1a,产率为80.3%。HNMR(400Hz,DMSO):7.92-7.90(d,J=4.8Hz,2H),7.50-7.48(d,J=4.8Hz,2H),7.37-7.35(d,J=4.4Hz,2H),7.18-7.16(d,J=4.4Hz,2H),6.55(s,2H),2.35(s,3H),2.24-2.20(m,2H),1.14(t,J=3.6Hz,3H);MS(m/z):460.4。
重复上述的反应步骤,得到24.2克化合物1b,产率为77.1%。HNMR(400Hz,DMSO):7.92-7.90(d,J=4.8Hz,2H),7.50-7.48(d,J=4.8Hz,2H),7.37-7.35(d,J=4.4Hz,2H),7.18-7.16(d,J=4.4Hz,2H),6.55(s,2H),2.35(s,3H),2.19-2.17(m,2H),1.63-1.61(m,2H),0.96(t,J=3.2Hz,3H);MS(m/z):474.3。
重复上述的反应步骤,得到23.7克化合物1c,产率为75.4%。HNMR(400Hz,DMSO):7.92-7.90(d,J=4.8Hz,2H),7.50-7.48(d,J=4.8Hz,2H),7.37-7.35(d,J=4.4Hz,2H),7.18-7.16(d,J=4.4Hz,2H),6.55(s,2H),2.35(s,3H),1.19-1.17(m,1H),0.71-0.68(m,2H),0.56-0.52(m,2H);MS(m/z):472.6。
实施例2:B16黑色素瘤抑制作用比较:
B16黑色素瘤于C57BL/6小鼠腋下皮下接种传代保存。选择肿瘤生长良好、无坏死或液化的腋下传代保存的B16黑色素瘤荷瘤小鼠,脱颈椎处死小鼠,75%酒精浸泡消毒后,无菌取瘤组织,加入5倍体积(W/V)的注射用生理盐水,用组织匀浆器制研磨成匀浆,以灭菌的200目不锈钢筛网过滤得瘤细胞悬液。同上接种于C57BL/6小鼠腋窝皮下,常规饲养。
分组和给药:荷瘤小鼠70只,按体重随机分为5组,每组10只,分别为模型组、环磷酰胺组、1a组、1b组、1c组、化合物Z组、塞来昔布组,剂量均为60mg/kg,采用生理盐水配制成3mg/ml溶液。各组小鼠按表3所示剂量和方式给药,环磷酰胺组于荷瘤第二天仅腹腔给予一次环磷酰胺,实验组的各组均每日尾静脉给药1次,连续10天。给药体积20ml/kg体重。末次给药后24小时,脱颈椎处死小鼠,称体重,剥取瘤组织称重,计算抑瘤率。
结果以SD表示,以t检验进行组间统计学差异比较。
结果显示,五个实验组连续静脉注射10天,均对小鼠移植性肿瘤B16黑色素瘤的生长具有抑制作用,化合物1c组最优。
与模型组比较:*,P<0.05;**,P<0.01。
实施例3:药动学试验
雄性beagle犬10只,每组2只,实验前一天晚禁食不禁水,给药前称重。
(A)塞来昔布组
(B)化合物Z组
(C)化合物1a组
(D)化合物1b组
(E)化合物1c组
给药:塞来昔布取200mg,其他组均计算成等同于塞来昔布200mg的质量,采用0.5%的CMC配制成10ml混悬液。单次给药10ml溶液后,给水10ml。检测条件:采用C18色谱柱,150mm×4.6mm,5um,流动相为30mmol/L的醋酸铵-甲醇(22:78V/V),流速:1ml/min,柱温:40°C,检测波长:254nm。给药后在0-24小时按时间点采血,采用验证的高效液相色谱法检测塞来昔布的血液血浆浓度,各组的表2:塞来昔布在各组中的血浆药物代谢动力学参数如下:
实施例4:化合物1c对小鼠热板法致痛的影响
选用体重20-22g雌性昆明种小鼠。首先进行痛觉敏感性筛选,将小鼠置于55.0℃±0.5℃的热板上,以小鼠舔后足所经历的时间作为疼痛反应的阈值,剔出喜跳者及小于5s或大于30s内无反应者,筛选出60只痛觉反应敏感的小鼠,按体重随机分成五组,每组12只。采用化合物1c进行实验。化合物1c低、中、高剂量组(化合物1c的剂量分别为4、12、36mg/kg体重)和阳性对照组(化合物Z,剂量为72mg/kg体重),采用0.5%的羧甲基纤维素钠溶液制备成混悬液。测定给药前痛阈值后,各试验组小鼠灌胃给予相应的药物,空白对照组给予等容积的生理盐水。用脱毛剂将小鼠双后足踝关节以下脱毛,擦干。每只小鼠以同样的方法测定给药前疼痛反应阈值,然后各受试组给药1h后,测定每鼠给药后的疼痛反应阈值,小鼠舔后足后,立即移离热板,于给药后的2h、3h再测定一次疼痛反应的阈值,对各组间疼痛反应的阈值进行t检验,以评价的镇痛作用。
试验结果如表3所示,表明各试验组小鼠给药前对热板法疼痛反应的阈值相近,经给药后,化合物1c各剂量组小鼠在1h、2h、3h舔后足的时间均较空白对照组显著延长,提高了疼痛反应的阈值,表明化合物1c能明显延长小鼠热板痛阈时间,具有显著的镇痛作用,药效显著优于化合物Z。表3中,低、中、高剂量组分别表示化合物1c低、中、高剂量组。
表31c对热板法实验中小鼠痛阈值的影响
Claims (5)
1.如式(I)所示结构的化合物:
式Ⅰ。
2.根据权利要求1所述化合物的盐。
3.权利要求1所述化合物的钠盐。
4.权利要求1、2、3所述化合物在制备治疗肿瘤药物中的用途。
5.权利要求1、2、3所述化合物在制备镇痛药物中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015102593383 | 2015-05-19 | ||
CN201510259338.3A CN104892514A (zh) | 2015-05-19 | 2015-05-19 | 一种咪唑类新化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105646354A true CN105646354A (zh) | 2016-06-08 |
CN105646354B CN105646354B (zh) | 2018-04-10 |
Family
ID=54025531
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510259338.3A Pending CN104892514A (zh) | 2015-05-19 | 2015-05-19 | 一种咪唑类新化合物 |
CN201610163381.4A Expired - Fee Related CN105646354B (zh) | 2015-05-19 | 2016-03-19 | 一种咪唑类化合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510259338.3A Pending CN104892514A (zh) | 2015-05-19 | 2015-05-19 | 一种咪唑类新化合物 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN104892514A (zh) |
WO (1) | WO2016184122A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106279353A (zh) * | 2016-03-18 | 2017-01-04 | 广州诺威生物技术有限公司 | 一种用于抗炎的化合物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104892514A (zh) * | 2015-05-19 | 2015-09-09 | 广州诺威生物技术有限公司 | 一种咪唑类新化合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004043934A1 (en) * | 2002-11-12 | 2004-05-27 | Pharmacia Corporation | Celecoxib prodrug |
CN1292746C (zh) * | 2001-04-17 | 2007-01-03 | 法马西亚公司 | 含具有氨基磺酰基的活性化合物、聚乙二醇和抗氧化剂的口服传递的药用组合物 |
WO2011163594A2 (en) * | 2010-06-24 | 2011-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1259504A1 (en) * | 2000-03-03 | 2002-11-27 | Pfizer Products Inc. | Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
EP1562914A1 (en) * | 2002-10-22 | 2005-08-17 | Merck Frosst Canada & Co. | Nitric oxide releasing selective cyclooxygenase-2 inhibitors |
CN104892514A (zh) * | 2015-05-19 | 2015-09-09 | 广州诺威生物技术有限公司 | 一种咪唑类新化合物 |
-
2015
- 2015-05-19 CN CN201510259338.3A patent/CN104892514A/zh active Pending
-
2016
- 2016-03-18 WO PCT/CN2016/000143 patent/WO2016184122A1/zh active Application Filing
- 2016-03-19 CN CN201610163381.4A patent/CN105646354B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1292746C (zh) * | 2001-04-17 | 2007-01-03 | 法马西亚公司 | 含具有氨基磺酰基的活性化合物、聚乙二醇和抗氧化剂的口服传递的药用组合物 |
WO2004043934A1 (en) * | 2002-11-12 | 2004-05-27 | Pharmacia Corporation | Celecoxib prodrug |
WO2011163594A2 (en) * | 2010-06-24 | 2011-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
Non-Patent Citations (2)
Title |
---|
AMJAD M. QANDIL,等: "Chemical and in vitro enzymatic stability of newly synthesized celecoxib lipophilic and hydrophilic amides", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 * |
RAO N.V.S. MAMIDI,等: "Pharmacological and Pharmacokinetic Evaluation of Celecoxib Prodrugs in Rats", 《BIOPHARMACEUTICS & DRUG DISPOSITION》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106279353A (zh) * | 2016-03-18 | 2017-01-04 | 广州诺威生物技术有限公司 | 一种用于抗炎的化合物 |
Also Published As
Publication number | Publication date |
---|---|
WO2016184122A1 (zh) | 2016-11-24 |
CN105646354B (zh) | 2018-04-10 |
CN104892514A (zh) | 2015-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102603743A (zh) | 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 | |
CN103923122B (zh) | 含有噁唑烷酮的二聚体化合物、组合物以及制备方法和用途 | |
CN108699024A (zh) | 苯并噻吩基选择性雌激素受体下调剂化合物 | |
US20220193106A1 (en) | Nucleobase analogue derivatives and their applications | |
JP2016500080A (ja) | ビスβ−カルボリン系化合物、その製造方法、医薬組成物および用途 | |
JP6978002B2 (ja) | チエノ−ピリミジン誘導体およびその使用 | |
US20130178470A1 (en) | Heterocyclic aminoberbamine derivatives, the preparation process and use thereof | |
CN113336768B (zh) | 一种多靶点酪氨酸激酶抑制剂 | |
CN101735276A (zh) | 水溶性磷酸单酯衍生物及其应用 | |
ES2615731T3 (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia | |
CN105646354A (zh) | 一种咪唑类化合物 | |
CN107162982A (zh) | 一类具有抗癌活性的咪唑类化合物及其衍生物 | |
RU2701728C2 (ru) | Новая поликристаллическая форма пролекарства тенофовира и способ ее получения и ее применение | |
CN106188068A (zh) | 3,6‑二芳基‑[1,2,4]三氮唑并[4,3‑b]哒嗪类化合物及用途 | |
CN104177377B (zh) | 3位双胺β-咔啉碱类化合物、其制法和其药物组合物与用途 | |
CN102746212B (zh) | β-榄香烯吲哚衍生物及其制备和应用 | |
JP2017513934A (ja) | フェナントロリンホスホン酸誘導体及びその調製方法と応用 | |
WO2011143864A1 (zh) | 抗癌用化合物及制备方法 | |
CN101659659B (zh) | 嘧啶衍生物及其医药用途 | |
CN107325052A (zh) | 一类具有抗癌活性的咪唑酯类化合物及其衍生物 | |
US20160102066A1 (en) | Benzothiazole derivative and anti-tumor use thereof | |
CN104672213A (zh) | 一种具有抗肿瘤活性的酰胺类化合物及其应用 | |
JP2018508495A (ja) | スニチニブのプロドラッグ及び医薬組成物 | |
CN103965202B (zh) | 二环稠合杂环化合物、其制备方法及用途 | |
CN102503908B (zh) | 维a酸衍生物、其制备方法、其药物组合物及其在制备抗肿瘤药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191206 Address after: No. 369, Guangyuan West Street, Yongnian District, Handan City, Hebei Province Patentee after: Hebei Jiupeng Pharmaceutical Co.,Ltd. Address before: 510630 science Avenue 97, Luogang District Development Zone, Guangdong, Guangzhou 1321 Patentee before: GUANGZHOU NUOWEI BIOTECHNOLOGY Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180410 |